Tests fexofenadine added to usual treatment for active rheumatoid arthritis
Tests fexofenadine or a placebo alongside standard treatment in adults with rheumatoid arthritis.
Plain-language title generated from the registry record
Registry title: Fexofenadine in Patients With Active Rheumatoid Arthritis
Key facts
- Where
- Banī Suwayf, EgyptSee the 2 sites
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT05264025, who can take part
Where in Egypt
- Beni suef hospitalBanī Suwayf, EgyptTaking people
- Faculty of Medicine - Beni Suef HospitalBanī Suwayf, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- October 6 University
- Trial code
- NCT05264025
- Record updated
- 31 July 2025
- Original description
Rheumatoid arthritis (RA) is an inflammatory autoimmune polyarthritis affecting ∼1% of the world population, resulting in the loss of joint function and progressive structural damage in affected joints. Fexofenadine has been widely used to treat various allergic diseases, like allergic rhinitis, conjunctivitis and chronic idiopathic urticaria. the molecular mechanisms underlying fexofenadine mediated inhibition of TNF-α signallingRead full original descriptionShow less
Fexofenadine as Adjunct to Standard Rheumatoid Therapy in Patients With Active Rheumatoid
Rheumatoid arthritis (RA) is an inflammatory autoimmune polyarthritis affecting ∼1% of the world population, resulting in the loss of joint function and progressive structural damage in affected joints. Fexofenadine has been widely used to treat various allergic diseases, like allergic rhinitis, conjunctivitis and chronic idiopathic urticaria. the molecular mechanisms underlying fexofenadine mediated inhibition of TNF-α signalling
Inclusion: Moderate to severe RA (disease activity score-28 joints: DAS-28 > 3.2) were recruited; Age between 18 - 60 years having active disease according to the diagnosis of an experienced rheumatologist, being under treatment with disease-modifying anti-rheumatic drugs (DMARDs), not receiving cytokine inhibitors; Signing informed consent and willingness of the participant to accept randomization to any assigned treatment arm.
Exclusion: Any changes in using medication (changing the dosage or type of medicines; Receive hormone replacement therapy, warfarin, and other anticoagulants; History of biological DMARDS; History/presence of acute heart disease, liver and kidney diseases, COPD; Intolerance or allergy to fexofenadine or methotrexate; Alcohol abuse.